BIODYNE CEO Ukbin Im Slightly Increases Stake to 40.72% via Open Market Purchase

BIODYNE's CEO and de facto controlling shareholder Ukbin Im acquired an additional 19,617 common shares at 10,478 KRW per share through open market purchase on July 3, 2026.
This purchase increased Im's total holdings to 12,119,888 shares, raising his ownership from 40.65% to 40.72%, a 0.07 percentage point increase.
The purchase price of 10,478 KRW is approximately 9.7% above the current closing price of 9,550 KRW as of the reporting date, suggesting management's perception of undervaluation and confidence in future growth despite recent price declines.
[AI Summary]The CEO's small-scale share buyback has limited short-term price impact but is interpreted as a positive signal of management confidence. The insignificant change in stake does not materially affect equity valuation.